ARCT Q4 2023 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena

ARCTArcturus Therapeutics Holdings Inc.

$217M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M-84.4% YoY

Gross Profit

$25M100.0% margin

Operating Income

-$18M-72.9% margin

Net Income

-$12M-46.7% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

-42.2%

Cash Flow

Operating Cash Flow

-$629,000

Free Cash Flow

-$2M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$429M

Total Liabilities

$151M

Stockholders' Equity

$279M

Cash & Equivalents

$292M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$160M	-84.4%
Gross Profit	$25M	$133M	-81.2%
Operating Income	-$18M	$121M	-115.0%
Net Income	-$12M	$117M	-110.0%

Revenue Segments

Collaboration Revenue

$78M100%